AR103629A1 - Compuestos con actividad antitumoral - Google Patents
Compuestos con actividad antitumoralInfo
- Publication number
- AR103629A1 AR103629A1 ARP160100337A ARP160100337A AR103629A1 AR 103629 A1 AR103629 A1 AR 103629A1 AR P160100337 A ARP160100337 A AR P160100337A AR P160100337 A ARP160100337 A AR P160100337A AR 103629 A1 AR103629 A1 AR 103629A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrr
- alkyl
- group
- hydrogen
- heterocycle
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 230000003381 solubilizing effect Effects 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- -1 1,2 diazinyl Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000001425 triazolyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 208000031295 Animal disease Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se relaciona con compuestos útiles para destruir, inhibir, o evitar el crecimiento o el esparcimiento de células, en especial de células malignas, dentro de los tejidos circundantes implicadas en una variedad de enfermedades humanas y animales. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: R¹, R², R⁴ y R⁵ son seleccionados cada uno independientemente de hidrógeno; heterociclo; ciano, -CF₃; -NRR; -OH; halógeno; grupo alquilo opcionalmente sustituido por uno o más grupos seleccionados de heterociclo, -NRR, -OR y un grupo solubilizante; grupo alcoxi opcionalmente sustituido por uno o más grupos seleccionados de heterociclo, -NRR, -OR y un grupo solubilizante; -CO-NRR; -SO₂-NRR; -NR-CO-R y -NR-SO₂R; en donde R y R son seleccionados cada uno independientemente de hidrógeno, cicloalquilo, heterociclo, grupo solubilizante y grupo alquilo opcionalmente sustituido por uno o más grupos seleccionados de OR, NRR, NRCOR y grupo solubilizante; en donde R y R son seleccionados cada uno independientemente de hidrógeno, alquilo y cicloalquilo; R³ es un hidrógeno; A es un grupo heterociclo, opcionalmente sustituido por uno o más grupos seleccionados de halógeno, alquilo, arilo, hidroxilo, alcoxi, nitro, tiol, heterocicloalquilo, heteroarilo, ciano, cicloalquilo, un grupo solubilizante, -NRR, -alquil-NRR; -NR-CO-R, -alquil-NR-CO-R, -CONRR y grupo -SO₂NRR; en donde R y R son seleccionados cada uno independientemente de hidrógeno, grupos alquilo, cicloalquilo, arilo, heterocicloalquilo y heteroarilo; B es un grupo arilo o un heteroarilo; X es N o C-R⁶, en donde R⁶ se selecciona de hidrógeno, ciano, CF₃, alquilo y alcoxi; con las condiciones de que B no es seleccionado de 1,2 diazinilo, triazolopiridinilo o triazolilo; si B es oxazolilo, A no es tetrazolilo o tetrahidropiridinilo; si B es tiazolilo, A no es imidazolilo, triazolilo, piperazinilo, pirrolidinilo, piperidinilo o 1,4-oxazinilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15154028.3A EP3053920B1 (en) | 2015-02-05 | 2015-02-05 | Compounds with anti-tumoral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103629A1 true AR103629A1 (es) | 2017-05-24 |
Family
ID=52450012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100337A AR103629A1 (es) | 2015-02-05 | 2016-02-05 | Compuestos con actividad antitumoral |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10570122B2 (es) |
| EP (2) | EP3053920B1 (es) |
| JP (1) | JP6713000B2 (es) |
| KR (1) | KR102544132B1 (es) |
| CN (1) | CN107531685B (es) |
| AR (1) | AR103629A1 (es) |
| AU (1) | AU2016214283B2 (es) |
| BR (1) | BR112017016883B1 (es) |
| CA (1) | CA2975644A1 (es) |
| CY (1) | CY1124948T1 (es) |
| DK (1) | DK3253749T3 (es) |
| ES (2) | ES2796276T3 (es) |
| HK (1) | HK1243700A1 (es) |
| HR (1) | HRP20220114T1 (es) |
| HU (1) | HUE059063T2 (es) |
| IL (1) | IL253779A0 (es) |
| LT (1) | LT3253749T (es) |
| MX (1) | MX2017010157A (es) |
| PL (1) | PL3253749T3 (es) |
| PT (1) | PT3253749T (es) |
| RS (1) | RS62901B1 (es) |
| RU (1) | RU2758259C2 (es) |
| TW (1) | TWI748938B (es) |
| WO (1) | WO2016124747A1 (es) |
| ZA (1) | ZA201705537B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106643A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| CN109467531A (zh) * | 2017-09-08 | 2019-03-15 | 沈阳科创化学品有限公司 | 一种取代吡啶二羧酸衍生物的制备方法 |
| CN112225733B (zh) * | 2020-11-25 | 2022-12-09 | 湖南科技大学 | 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用 |
| WO2024175803A1 (en) * | 2023-02-24 | 2024-08-29 | Ab Science | Compounds for treating myeloid diseases with chromosomal abnormalities |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US810665A (en) * | 1905-10-10 | 1906-01-23 | Joseph Mlada | Mold for butter. |
| US1346834A (en) * | 1918-08-17 | 1920-07-20 | Charles E Mcmanus | Resilient rod |
| US3740420A (en) | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
| US3743727A (en) | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| CA1163561A (en) | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4411893A (en) | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| CA1236029A (en) | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
| US4615699A (en) | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US6448272B1 (en) * | 1998-12-07 | 2002-09-10 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| JP4216947B2 (ja) * | 1999-05-18 | 2009-01-28 | 三井化学株式会社 | アミン化合物 |
| CN100491374C (zh) * | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| BRPI0410348A (pt) * | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compostos e usos dos mesmos na modulação de amilóide-beta |
| ATE465731T1 (de) * | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| EP1786781A2 (en) * | 2004-08-27 | 2007-05-23 | GPC Biotech AG | Pyrimidine derivatives |
| CN101217954B (zh) * | 2005-04-04 | 2013-07-10 | Ab科学公司 | 经取代的噁唑衍生物及其作为酪氨酸激酶抑制剂的用途 |
| AP2358A (en) * | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
| JP5214096B2 (ja) * | 2005-06-17 | 2013-06-19 | 富士フイルムファインケミカルズ株式会社 | 新規なビピリジン誘導体 |
| EP1904065A2 (en) * | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| ES2632940T3 (es) * | 2005-09-13 | 2017-09-18 | Janssen Pharmaceutica Nv | Derivados de tiazol sustituidos con 2-anilin-4-arilo |
| GB0524436D0 (en) * | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| AU2007245059B2 (en) * | 2006-03-31 | 2011-07-28 | Novartis Ag | New compounds |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| US8080669B2 (en) | 2006-05-12 | 2011-12-20 | Ab Science | Process for the synthesis of 2-aminoxazole compounds |
| FR2901273B1 (fr) * | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| CL2008000192A1 (es) * | 2007-01-23 | 2008-07-25 | Palau Pharma Sa | Compuestos derivados de purina sustituidos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo a transplantes, leucemias, diabetes, entre otras. |
| JP2010519258A (ja) * | 2007-02-22 | 2010-06-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体 |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2310384B1 (en) * | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2012180281A (ja) * | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
| WO2011006903A1 (en) * | 2009-07-15 | 2011-01-20 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| WO2011057214A2 (en) * | 2009-11-09 | 2011-05-12 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| KR101750125B1 (ko) * | 2010-01-12 | 2017-06-22 | 에이비 사이언스 | 티아졸 및 옥사졸 키나제 저해제 |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| US20130165440A1 (en) * | 2010-09-14 | 2013-06-27 | Exelixis, Inc. | JAK1 Inhibitors |
| US20120129843A1 (en) * | 2010-11-18 | 2012-05-24 | Yan Zhang | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US20120302569A1 (en) * | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US8551992B2 (en) * | 2011-05-27 | 2013-10-08 | Neosome Life Sciences, LLC | Aminooxazole inhibitors of cyclin dependent kinases |
| MX2014001079A (es) * | 2011-07-27 | 2014-09-12 | Ab Science | Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit). |
| KR101896035B1 (ko) * | 2011-08-23 | 2018-09-07 | 덕산네오룩스 주식회사 | 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말 |
| CN103436048B (zh) * | 2013-08-08 | 2014-12-03 | 陕西师范大学 | 硫脲供体双桥链有机染料及其应用 |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| WO2015144614A1 (en) * | 2014-03-24 | 2015-10-01 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
| EP3144307A1 (en) * | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
-
2015
- 2015-02-05 EP EP15154028.3A patent/EP3053920B1/en active Active
- 2015-02-05 ES ES15154028T patent/ES2796276T3/es active Active
-
2016
- 2016-02-05 BR BR112017016883-9A patent/BR112017016883B1/pt active IP Right Grant
- 2016-02-05 DK DK16703138.4T patent/DK3253749T3/da active
- 2016-02-05 WO PCT/EP2016/052523 patent/WO2016124747A1/en active Application Filing
- 2016-02-05 MX MX2017010157A patent/MX2017010157A/es active IP Right Grant
- 2016-02-05 RU RU2017127484A patent/RU2758259C2/ru not_active Application Discontinuation
- 2016-02-05 LT LTEPPCT/EP2016/052523T patent/LT3253749T/lt unknown
- 2016-02-05 HR HRP20220114TT patent/HRP20220114T1/hr unknown
- 2016-02-05 EP EP16703138.4A patent/EP3253749B1/en active Active
- 2016-02-05 RS RS20220136A patent/RS62901B1/sr unknown
- 2016-02-05 US US15/548,451 patent/US10570122B2/en active Active
- 2016-02-05 HU HUE16703138A patent/HUE059063T2/hu unknown
- 2016-02-05 CA CA2975644A patent/CA2975644A1/en active Pending
- 2016-02-05 TW TW105103940A patent/TWI748938B/zh not_active IP Right Cessation
- 2016-02-05 JP JP2017539023A patent/JP6713000B2/ja active Active
- 2016-02-05 PT PT167031384T patent/PT3253749T/pt unknown
- 2016-02-05 ES ES16703138T patent/ES2905412T3/es active Active
- 2016-02-05 KR KR1020177022077A patent/KR102544132B1/ko active IP Right Grant
- 2016-02-05 AR ARP160100337A patent/AR103629A1/es unknown
- 2016-02-05 AU AU2016214283A patent/AU2016214283B2/en active Active
- 2016-02-05 PL PL16703138T patent/PL3253749T3/pl unknown
- 2016-02-05 CN CN201680008641.9A patent/CN107531685B/zh active Active
-
2017
- 2017-08-01 IL IL253779A patent/IL253779A0/en active IP Right Grant
- 2017-08-15 ZA ZA201705537A patent/ZA201705537B/en unknown
-
2018
- 2018-03-01 HK HK18103001.1A patent/HK1243700A1/zh unknown
-
2022
- 2022-02-02 CY CY20221100089T patent/CY1124948T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CU24496B1 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR091490A1 (es) | Antagonistas de iap | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR103629A1 (es) | Compuestos con actividad antitumoral | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |